Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.
Paller CJ, Barata PC, Lorentz J, Appleman LJ, Armstrong AJ, DeMarco TA, Dreicer R, Elrod JAB, Fleming M, George C, Heath EI, Hussain MHA, Mao S, McKay RR, Morgans AK, Orton M, Pili R, Riedel E, Saraiya B, Sigmond J, Sokolova A, Stadler WM, Tran C, Macario N, Vinson J, Green R, Cheng HH; PROMISE Trial Investigators. Paller CJ, et al. Among authors: saraiya b. Prostate. 2024 Feb;84(3):292-302. doi: 10.1002/pros.24650. Epub 2023 Nov 14. Prostate. 2024. PMID: 37964482
Oncologists and end-of-life care.
Saraiya B. Saraiya B. J Palliat Med. 2009 Feb;12(2):116. doi: 10.1089/jpm.2008.0233. J Palliat Med. 2009. PMID: 19207050 No abstract available.
Genomic analysis and long-term outcomes of a phase 1 clinical trial on cytoreductive radical prostatectomy.
Kim IY, Mitrofanova A, Panja S, Sterling J, Srivastava A, Kim J, Kim S, Singer EA, Jang TL, Ghodoussipour S, Saraiya B, Mayer T, Sabaawy HE, Yuh B, Byun SS, Kim WJ, Horie S. Kim IY, et al. Among authors: saraiya b. Prostate Int. 2022 Jun;10(2):75-79. doi: 10.1016/j.prnil.2022.03.001. Epub 2022 Mar 9. Prostate Int. 2022. PMID: 35510081 Free PMC article.
A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE).
Pan E, Xie W, Ajmera A, Araneta A, Jamieson C, Folefac E, Hussain A, Kyriakopoulos CE, Olson A, Parikh M, Parikh R, Saraiya B, Ivy SP, Van Allen EM, Lindeman NI, Kochupurakkal BS, Shapiro GI, McKay RR. Pan E, et al. Among authors: saraiya b. Mol Cancer Ther. 2023 Apr 3;22(4):511-518. doi: 10.1158/1535-7163.MCT-22-0583. Mol Cancer Ther. 2023. PMID: 36780008 Free PMC article. Clinical Trial.
PIK3/Akt/mTOR pathway alterations in metastatic castration-sensitive prostate cancer.
Sutera P, Kim J, Kumar R, Deek RA, Stephenson R, Mayer T, Saraiya B, Ghodoussipour S, Jang T, Golombos D, Packiam V, Ennis R, Hathout L, Jabbour SK, Guler O, Onal C, Tran PT, Deek MP. Sutera P, et al. Among authors: saraiya b. Prostate. 2024 Oct;84(14):1301-1308. doi: 10.1002/pros.24765. Epub 2024 Jul 17. Prostate. 2024. PMID: 39021052
Impact of pathologic lymph node-positive renal cell carcinoma on survival in patients without metastasis: Evidence in support of expanding the definition of stage IV kidney cancer.
Srivastava A, Rivera-Núñez Z, Kim S, Sterling J, Farber NJ, Radadia KD, Patel HV, Modi PK, Goyal S, Parikh R, Mayer TM, Saraiya B, Sadimin ET, Weiss RE, Kim IY, Elsamra SE, Jang TL, Singer EA. Srivastava A, et al. Among authors: saraiya b. Cancer. 2020 Jul 1;126(13):2991-3001. doi: 10.1002/cncr.32912. Epub 2020 Apr 24. Cancer. 2020. PMID: 32329899 Free article.
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang YH, Lee JL, Sarwar N, Haas NB, Gurney H, Sawrycki P, Mahave M, Gross-Goupil M, Zhang T, Burke JM, Doshi G, Melichar B, Kopyltsov E, Alva A, Oudard S, Topart D, Hammers H, Kitamura H, McDermott DF, Silva A, Winquist E, Cornell J, Elfiky A, Burgents JE, Perini RF, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2024 Apr 18;390(15):1359-1371. doi: 10.1056/NEJMoa2312695. N Engl J Med. 2024. PMID: 38631003 Clinical Trial.
Prostate-Specific Membrane Antigen PET Response Associates with Metastasis-Free Survival After Stereotactic Ablative Radiation in Oligometastatic Prostate Cancer.
Sutera P, Deek MP, Deek RA, Guler OC, Hurmuz P, Reyhan M, Rowe S, Radwan N, Dipasquale S, Hrinivich WT, Lowe K, Ren L, Saraiya B, Ennis R, Hathout L, Mayer T, Deweese TL, Song DY, Kiess A, Oymak E, Pienta K, Feng F, Pomper M, Ozyigit G, Tran PT, Onal C, Phillips RM. Sutera P, et al. Among authors: saraiya b. Adv Radiat Oncol. 2024 Apr 13;9(7):101507. doi: 10.1016/j.adro.2024.101507. eCollection 2024 Jul. Adv Radiat Oncol. 2024. PMID: 38799104 Free PMC article.
47 results